Drug intelligence / Profile preview

helenalin

Development stage
Preclinical
Modality
Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Topical, Oral
01

Overview

Helenalin is a naturally occurring sesquiterpene lactone found in plants such as Arnica montana and Arnica chamissonis. It is primarily responsible for the toxicity of these species. Despite its toxicity to humans and animals if ingested in significant amounts, helenalin has demonstrated notable anti-inflammatory and antineoplastic (anti-cancer) effects in vitro. Its mechanism of action includes selective inhibition of the transcription factor NF-kappaB by modifying the NF-kappaB/IkappaB complex and preventing activation-driven gene expression. This effect differs from that of traditional NSAIDs. Helenalin also induces oxidative stress through reactive oxygen species generation and can inhibit enzymes such as 5-lipoxygenase and leukotriene C4 synthase. Additionally, it can interact with proteins via Michael addition to thiol groups on cysteine residues—disrupting protein function—and inhibits human cytochrome P450 enzymes (notably CYP3A4/3A5/2A13). While used traditionally as an anti-inflammatory agent in folk medicine (mainly topically), it is not approved as a pharmaceutical drug due to its toxicity profile[1][2][6][7].

Other names
(-)-4-Hydroxy-4a,8-dimethyl-3,3a,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione6754-13-8
02

Targets

CYP3A4 (Cytochrome P450 3A4)CYP2A13 (Cytochrome P450 2A13)RELA (Nuclear Factor Kappa B Subunit p65)

Beyond the preview

Go deeper on helenalin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on helenalin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call